Racial Disparities in Incidence and Survival for Patients with Multiple Myeloma in the United States

Conference Correspondent  - TON - ASH 2015 - Multiple Myeloma, Conference Correspondent

The incidence of multiple myeloma is nearly 2-fold higher in African Americans than in whites. There are also differences in overall survival between the 2 races. This difference is not completely explained by racial disparities, and researchers postulate that some of the differences may be attributable to genetic variations between the 2 groups.

Using data from the National Cancer Institute, researchers examined differences in the incidence, mortality, and survival of 68,701 white, 16,364 black, and 4802 other patients with MM who were classified by race, sex, and age, from 1973 to 2012. Age-adjusted incidence and mortality rates, regression analysis, and survival curves were calculated by race. Median age at diagnosis was 66 years for African Americans and 71 years for whites (P <.01).

The age-adjusted incidence rates per 100,000 population for African Americans (11.9; P <.05) were more than double the corresponding rates for whites (5.1). African Americans present with myeloma at a lower age compared with whites, and this difference was seen during the course of the study.

Although 5-year relative survival is improving for all races and sexes, the survival analysis showed that African American race is an independent factor for improved survival (hazard ratio, 0.884; P <.0001). Further population-based studies focused on how exploring the underlying biologic mechanisms of disease may explain unanswered questions such as higher incidence rates and better overall survival among African American patients.

Related Items
Emerging Safety Data with Checkpoint Inhibitors
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Psychological Distress in Patients with Cancer Warrants Attention
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Patients’ Chemotherapy-Related Side-Effect Concerns Have Evolved, But Hair Loss Remains Significant
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Increased Cancer Risk in Postmenopausal Women with Central Obesity
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Patients’ Fears of Radiation Side Effects Largely Unfounded
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Netupitant plus Palonosetron Noninferior to Aprepitant plus Granisetron in Patients Receiving Highly Emetogenic Chemotherapy
Li Zhang, MD
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Patient-Reported Outcomes Influence Radiation Guidelines
Alice Goodman
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Healthy Lifestyle Improves Survival in Patients with Colon Cancer
Phoebe Starr
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Colorectal Cancer, Conference Correspondent
8-Week Internet-Based Psychological Intervention Reduces Stress in Patients Newly Diagnosed with Cancer
Phoebe Starr
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Hair Loss Seen in 1 of 3 Women with Breast Cancer Receiving Endocrine Therapy
Alice Goodman
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Last modified: December 5, 2017